针对泛癌干:核心调控性 lncRNAs 作为新的治疗漏洞
Shengcheng Deng1, Yufan Yang1, Dapeng Gao1
1MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China.
International journal of molecular sciences
|December 11, 2025
概括
这项研究揭示了非编码RNA (lncRNAs) 驱动瘤干的时间,影响癌症的进展和治疗耐药性. 像NEAT1和MALAT1这样的关键lncRNA被确定为侵略性癌症的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 瘤干对于癌症的进展和治疗耐药性至关重要.
- 长非编码RNAs (lncRNAs) 参与调节瘤干的作用.
- 了解ncRNA的作用对于开发新的癌症治疗方法至关重要.
研究的目的:
- 系统地研究lncRNAs在瘤干性中的调节作用.
- 为了识别与各种癌症类型的茎性相关的lncRNA签名.
- 开发基于lncRNA表达的预后模型,用于预测患者的结果.
主要方法:
- 癌症基因组图谱 (TCGA) 大量转录组数据与泛癌单细胞图谱的整合.
- 基于机器学习的干度指标的应用,以量化干度特征.
- 使用已识别的 lncRNA 基因组构建预后模型.
主要成果:
- 鉴定了与干性相关的癌症类型特定的 lncRNA 基因组.
- 高干性亚型显示增加了扩散,免疫抑制和代谢重编程.
- 开发了一个强大的预后模型,在多种癌症中具有高预测性能.
- 在单细胞分辨率下重建了干细胞进化轨迹,揭示了CSC特定的模式.
- 一致指定的核心调节性 lncRNAs,包括 NEAT1 和 MALAT1.
结论:
- lncRNAs在驱动瘤干,进展和抵抗方面发挥着重要作用.
- NEAT1和MALAT1是癌症干细胞的关键调节性 lncRNA.
- 这项研究为了解 lncRNA 驱动的癌症攻击性提供了一个框架,并确定了潜在的治疗点.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


